Details for New Drug Application (NDA): 207771
✉ Email this page to a colleague
NDA 207771 describes AMLODIPINE AND OLMESARTAN MEDOXOMIL, which is a drug marketed by Accord Hlthcare Inc, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd V, Jubilant Generics, Macleods Pharms Ltd, Micro Labs, Sciegen Pharms Inc, Teva Pharms Usa, Torrent, and Zydus Pharms, and is included in fourteen NDAs. It is available from thirteen suppliers. Additional details are available on the AMLODIPINE AND OLMESARTAN MEDOXOMIL profile page.
The generic ingredient in AMLODIPINE AND OLMESARTAN MEDOXOMIL is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
The generic ingredient in AMLODIPINE AND OLMESARTAN MEDOXOMIL is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
Summary for 207771
| Tradename: | AMLODIPINE AND OLMESARTAN MEDOXOMIL |
| Applicant: | Zydus Pharms |
| Ingredient: | amlodipine besylate; olmesartan medoxomil |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE;20MG | ||||
| Approval Date: | Sep 22, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE;40MG | ||||
| Approval Date: | Sep 22, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE;20MG | ||||
| Approval Date: | Sep 22, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
